The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 18, 2021
Filed:
Nov. 23, 2016
Applicants:
Katholieke Universiteit Leuven, Leuven, BE;
Université Libre DE Bruxelles, Brussels, BE;
Inventors:
Steven De Vleeschouwer, Heverlee, BE;
Matthias Van Woensel, Westerlo, BE;
Karim Amighi, Brussels, BE;
Nathalie Wauthoz, Brussels, BE;
Rémi Rosiere, Brussels, BE;
Assignees:
KATHOLIEKE UNIVERSITEIT LEUVEN, Leuven, BE;
UNIVERSITÉ LIBRE DE BRUXELLES, Brussels, BE;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/04 (2006.01); A61K 9/51 (2006.01); A61K 9/00 (2006.01); A61P 35/00 (2006.01); A61K 31/7105 (2006.01); A61K 47/69 (2017.01); A61K 47/36 (2006.01);
U.S. Cl.
CPC ...
A61K 9/5161 (2013.01); A61K 9/0043 (2013.01); A61K 31/7105 (2013.01); A61P 35/00 (2018.01); A61K 9/5192 (2013.01); A61K 47/36 (2013.01); A61K 47/6939 (2017.08);
Abstract
The present invention generally relates to a new formulation containing nanoparticles encapsulating siRNA for the use of RNAi technology for gene silencing of galectin-1 involved in tumour progression. More in particular the present invention relates to the use of RNAi molecules for treating central nervous cancer, more in particular for treating glioblastoma multiforme (GBM).